Diabetes Care, Vol 21, Issue 2 283-290, Copyright © 1998 by American Diabetes Association

ARTICLES

Effects of glycemic control on protective responses against hypoglycemia in type 2 diabetes

A Korzon-Burakowska, D Hopkins, K Matyka, J Lomas, A Pernet, I Macdonald and S Amiel
Department of Medicine, King's College School of Medicine and Dentistry, London, UK.

OBJECTIVE: To determine the effects of glycemic control on the counterregulatory responses to hypoglycemia in type 2 diabetes. RESEARCH DESIGN AND METHODS: Seven poorly controlled type 2 diabetes patients (mean HbA1c, 11.3 +/- 1.1%) were studied by stepped hyperinsulinemic hypoglycemic clamp (nadir, 2.4 mmol/l) before and after improving glycemic control with insulin treatment. Counterregulatory hormones, symptoms, and four-choice reaction time were measured at each glucose plateau. RESULTS: In patients with poorly controlled type 2 diabetes, counterregulatory hormone responses began at higher plasma glucose levels than did those in healthy subjects (epinephrine, 4.4 +/- 0.2 vs. 3.7 +/- 0.2 mmol/l, P = 0.011). After significant improvement in glycemic control (mean HbA1c, 8.1 +/- 0.9%, P < 0.001) was achieved without severe hypoglycemia, hormonal responses started at much lower plasma glucose levels (e.g., epinephrine, 3.5 +/- 0.3 mmol/l, P = 0.005) and were significantly reduced in magnitude (e.g., area under epinephrine response curve, 306 +/- 93 vs. 690 +/- 107 nmol.min-1.l-1, P = 0.012). This was accompanied by a change in the plasma glucose threshold at which hypoglycemic symptoms first developed from 3.6 +/- 0.2 to 3.0 +/- 0.2 mmol/l (P = 0.019). In contrast, the plasma glucose threshold at which four-choice reaction time deteriorated did not change significantly (3.1 +/- 0.1 vs. 2.9 +/- 0.1 mmol/l, P = 0.125). CONCLUSIONS: Counterregulatory responses begin at normoglycemia in poorly controlled type 2 diabetes. Improving glycemic control with insulin therapy normalizes hormonal responses but lowers the plasma glucose levels at which hypoglycemic symptoms develop to levels associated with impairment of four-choice reaction time, a marker of cognitive function. This process potentially increases the risk of severe hypoglycemia, but to a lesser extent than occurs in type 1 disease.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				V. J. Briscoe and S. N. Davis Hypoglycemia in Type 1 and Type 2 Diabetes: Physiology, Pathophysiology, and Management Clin. Diabetes, July 1, 2006; 24(3): 115 - 121. [Abstract] [Full Text] [PDF]

				N. N. Zammitt and B. M. Frier Hypoglycemia in Type 2 Diabetes: Pathophysiology, frequency, and effects of different treatment modalities Diabetes Care, December 1, 2005; 28(12): 2948 - 2961. [Full Text] [PDF]

				C. G. Parkin and N. Brooks Is Postprandial Glucose Control Important? Is It Practical In Primary Care Settings? Clin. Diabetes, April 1, 2002; 20(2): 71 - 76. [Abstract] [Full Text] [PDF]

				M. R. Burge, T. A. Sobhy, C. R. Qualls, and D. S. Schade Effect of Short-Term Glucose Control on Glycemic Thresholds for Epinephrine and Hypoglycemic Symptoms J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5471 - 5478. [Abstract] [Full Text] [PDF]

				K. M. Oltmanns, B. Fruehwald-Schultes, W. Kern, J. Born, H. L. Fehm, and A. Peters Hypoglycemia, But Not Insulin, Acutely Decreases LH and T Secretion in Men J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4913 - 4919. [Abstract] [Full Text] [PDF]

				B. Fruehwald-Schultes, W. Kern, K. M. Oltmanns, S. Sopke, B. Toschek, J. Born, H. L. Fehm, and A. Peters Metformin Does Not Adversely Affect Hormonal and Symptomatic Responses to Recurrent Hypoglycemia J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4187 - 4192. [Abstract] [Full Text] [PDF]

				C. D. Miller, L. S. Phillips, D. C. Ziemer, D. L. Gallina, C. B. Cook, and I. M. El-Kebbi Hypoglycemia in Patients With Type 2 Diabetes Mellitus Arch Intern Med, July 9, 2001; 161(13): 1653 - 1659. [Abstract] [Full Text] [PDF]

				L. Landstedt-Hallin, U. Adamson, and P.-E. Lins Oral Glibenclamide Suppresses Glucagon Secretion during Insulin-Induced Hypoglycemia in Patients with Type 2 Diabetes J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3140 - 3145. [Abstract] [Full Text]